Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 7/2012

Open Access 01-10-2012 | Original

The human μ-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients

Authors: S. Menon, R. A. Lea, B. Roy, M. Hanna, S. Wee, L. M. Haupt, L. R. Griffiths

Published in: The Journal of Headache and Pain | Issue 7/2012

Login to get access

Abstract

Migraine is a painful and debilitating, neurovascular disease. Current migraine head pain treatments work with differing efficacies in migraineurs. The opioid system plays an important role in diverse biological functions including analgesia, drug response and pain reduction. The A118G single nucleotide polymorphism (SNP) in exon 1 of the μ-opioid receptor gene (OPRM1) has been associated with elevated pain responses and decreased pain threshold in a variety of populations. The aim of the current preliminary study was to test whether genotypes of the OPRM1 A118G SNP are associated with head pain severity in a clinical cohort of female migraineurs. This was a preliminary study to determine whether genotypes of the OPRM1 A118G SNP are associated with head pain severity in a clinical cohort of female migraineurs. A total of 153 chronic migraine with aura sufferers were assessed for migraine head pain using the Migraine Disability Assessment Score instrument and classified into high and low pain severity groups. DNA was extracted and genotypes obtained for the A118G SNP. Logistic regression analysis adjusting for age effects showed the A118G SNP of the OPRM1 gene to be significantly associated with migraine pain severity in the test population (P = 0.0037). In particular, G118 allele carriers were more likely to be high pain sufferers compared to homozygous carriers of the A118 allele (OR = 3.125, 95 % CI = 1.41, 6.93, P = 0.0037). These findings suggest that A118G genotypes of the OPRM1 gene may influence migraine-associated head pain in females. Further investigations are required to fully understand the effect of this gene variant on migraine head pain including studies in males and in different migraine subtypes, as well as in response to head pain medication.
Literature
1.
Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL (2005) Migraine: current concepts and emerging therapies. Vasc Pharmacol 43(3):176–187, 10.1016/j.vph.2005.07.001, 1:CAS:528:DC%2BD2MXos1agt7s%3DCrossRef
2.
Goadsby PJ (2005) Migraine pathophysiology. Headache 45(Suppl 1):S14–S24, 15833086, 10.1111/j.1526-4610.2005.4501003.xCrossRefPubMed
3.
Cerbo R, Pesare M, Aurilia C, Rondelli V, Barbanti P (2001) Socio-economic costs of migraine. J Headache Pain 2:S15–S19, 10.1007/s101940170003PubMedCentralCrossRef
4.
Mett A, Tfelt-Hansen P (2008) Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 21(3):331–337, 18451718, 10.1097/WCO.0b013e3282fee843, 1:CAS:528:DC%2BD1cXntlSmtbs%3DCrossRefPubMed
5.
Society HCSotiH (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl 1):1–60
6.
Engindeniz Z, Demircan C, Karli N, Armagan E, Bulut M, Aydin T, Zarifoglu M (2005) Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. J Headache Pain 6(3):143–148, 16355295, 10.1007/s10194-005-0169-y, 1:CAS:528:DC%2BD2MXlvVWqsrc%3DPubMedCentralCrossRefPubMed
7.
Vossen H, Kenis G, Rutten B, van Os J, Hermens H, Lousberg R (2010) The genetic influence on the cortical processing of experimental pain and the moderating effect of pain status. PLoS One 5(10):e13641, 21049025, 10.1371/journal.pone.0013641PubMedCentralCrossRefPubMed
8.
Nielsen CS, Stubhaug A, Price DD, Vassend O, Czajkowski N, Harris JR (2008) Individual differences in pain sensitivity: genetic and environmental contributions. Pain 136(1–2):21–29, 17692462, 10.1016/j.pain.2007.06.008CrossRefPubMed
9.
Norbury TA, MacGregor AJ, Urwin J, Spector TD, McMahon SB (2007) Heritability of responses to painful stimuli in women: a classical twin study. Brain 130(Pt 11):3041–3049, 17932101, 10.1093/brain/awm233CrossRefPubMed
10.
Honkasalo ML, Kaprio J, Winter T, Heikkila K, Sillanpaa M, Koskenvuo M (1995) Migraine and concomitant symptoms among 8167 adult twin pairs. Headache 35(2):70–78, 7737864, 10.1111/j.1526-4610.1995.hed3502070.x, 1:STN:280:DyaK2M3ls1SmsA%3D%3DCrossRefPubMed
11.
Larsson B, Bille B, Pedersen NL (1995) Genetic influence in headaches: a Swedish twin study. Headache 35(9):513–519, 8530274, 10.1111/j.1526-4610.1995.hed3509513.x, 1:STN:280:DyaK28%2FosVCrsg%3D%3DCrossRefPubMed
12.
Ziegler DK, Hur YM, Bouchard TJ Jr, Hassanein RS, Barter R (1998) Migraine in twins raised together and apart. Headache 38(6):417–422, 9664744, 10.1046/j.1526-4610.1998.3806417.x, 1:STN:280:DyaK1czivFCntA%3D%3DCrossRefPubMed
13.
Treloar SA, Martin NG, Heath AC (1998) Longitudinal genetic analysis of menstrual flow, pain, and limitation in a sample of Australian twins. Behav Genet 28(2):107–116, 9583236, 10.1023/A:1021419907305, 1:STN:280:DyaK1c3ksVSksw%3D%3DCrossRefPubMed
14.
Bengtsson B, Thorson J (1991) Back pain: a study of twins. Acta geneticae medicae et gemellologiae 40(1):83–90, 1835236, 1:STN:280:DyaK38%2FlslCnsQ%3D%3DPubMed
15.
Heikkila JK, Koskenvuo M, Heliovaara M, Kurppa K, Riihimaki H, Heikkila K, Rita H, Videman T (1989) Genetic and environmental factors in sciatica. Evidence from a nationwide panel of 9365 adult twin pairs. Ann Med 21(5):393–398, 2605032, 10.3109/07853898909149227, 1:STN:280:DyaK3c7gsFShsA%3D%3DCrossRefPubMed
16.
Kim H, Neubert JK, San Miguel A, Xu K, Krishnaraju RK, Iadarola MJ, Goldman D, Dionne RA (2004) Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 109(3):488–496, 15157710, 10.1016/j.pain.2004.02.027CrossRefPubMed
17.
Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (New York, NY) 299(5610):1240–1243
18.
Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I (2005) How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 26(6):311–317, 15925706, 10.1016/j.tips.2005.04.001, 1:CAS:528:DC%2BD2MXltFegt7o%3DCrossRefPubMed
19.
Zhang W, Chang YZ, Kan QC, Zhang LR, Lu H, Chu QJ, Wang ZY, Li ZS, Zhang J (2010) Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 65(2):130–135, 20003118, 10.1111/j.1365-2044.2009.06193.x, 1:CAS:528:DC%2BC3cXitlKmsrY%3DCrossRefPubMed
20.
Silberstein SD, Lipton RB (1994) Overview of diagnosis and treatment of migraine. Neurology 44(10 Suppl 7):S6–S16, 7969947, 1:STN:280:DyaK2M%2FlvF2kuw%3D%3DPubMed
21.
Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, Teo YY, Tan EC (2008) A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109(3):520–526, 18719451, 10.1097/ALN.0b013e318182af21, 1:CAS:528:DC%2BD1cXhtVWntr7ECrossRefPubMed
22.
Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT (2009) Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Molecular pain 5:32, 19545447, 10.1186/1744-8069-5-32PubMedCentralCrossRefPubMed
23.
Uhl GR, Sora I, Wang Z (1999) The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Nat Acad Sci USA 96(14):7752–7755, 10393893, 10.1073/pnas.96.14.7752, 1:CAS:528:DyaK1MXltVOkt74%3DPubMedCentralCrossRefPubMed
24.
Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Nat Acad Sci USA 95(16):9608–9613, 9689128, 10.1073/pnas.95.16.9608, 1:CAS:528:DyaK1cXltlClsbY%3DPubMedCentralCrossRefPubMed
25.
Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280(38):32618–32624, 16046395, 10.1074/jbc.M504942200, 1:CAS:528:DC%2BD2MXhtVWiur7ICrossRefPubMed
26.
Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, Mogil JS, Wallace MR (2005) The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 6(3):159–167, 15772909, 10.1016/j.jpain.2004.11.008, 1:CAS:528:DC%2BD2MXisVCmu74%3DCrossRefPubMed
27.
Campa D, Gioia A, Tomei A, Poli P, Barale R (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83(4):559–566, 17898703, 10.1038/sj.clpt.6100385, 1:CAS:528:DC%2BD1cXjsFClu7s%3DCrossRefPubMed
28.
Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ (2006) Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50(7):787–792, 16879459, 10.1111/j.1399-6576.2006.01058.x, 1:CAS:528:DC%2BD28XpsVCis70%3DCrossRefPubMed
29.
Mague SD, Blendy JA (2010) OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108(3):172–182, 20074870, 10.1016/j.drugalcdep.2009.12.016, 1:CAS:528:DC%2BC3cXlsFSns7c%3DPubMedCentralCrossRefPubMed
30.
Belfer I, Wu T, Kingman A, Krishnaraju RK, Goldman D, Max MB (2004) Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology 100(6):1562–1572, 15166579, 10.1097/00000542-200406000-00032CrossRefPubMed
31.
Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L (2009) The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics 19(6):422–428, 19384265, 10.1097/FPC.0b013e32832af5a3, 1:CAS:528:DC%2BD1MXmtFKhurs%3DCrossRefPubMed
32.
Lea RA, Ovcaric M, Sundholm J, MacMillan J, Griffiths LR (2004) The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med 2:3, 15053827, 10.1186/1741-7015-2-3PubMedCentralCrossRefPubMed
33.
Wessman M, Terwindt GM, Kaunisto MA, Palotie A, Ophoff RA (2007) Migraine: a complex genetic disorder. Lancet Neurol 6(6):521–532, 17509487, 10.1016/S1474-4422(07)70126-6, 1:CAS:528:DC%2BD2sXmslKktrw%3DCrossRefPubMed
34.
Fillingim RB, Edwards RR, Powell T (2000) Sex-dependent effects of reported familial pain history on recent pain complaints and experimental pain responses. Pain 86(1–2):87–94, 10779665, 10.1016/S0304-3959(00)00239-6, 1:STN:280:DC%2BD3c3ktlKqsw%3D%3DCrossRefPubMed
35.
Ruau D, Liu LY, Clark JD, Angst MS, Butte AJ (2012) Sex differences in reported pain across 11,000 patients captured in electronic medical records. J Pain 13(3):228–234, 22245360, 10.1016/j.jpain.2011.11.002PubMedCentralCrossRefPubMed
36.
Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J (1999) Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 19(2):107–114 (discussion 174), 10214536, 10.1046/j.1468-2982.1999.019002107.x, 1:STN:280:DyaK1M3jtFWmsw%3D%3D, (discussion 174)CrossRefPubMed
37.
Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53(5):988–994, 10496257, 10.1212/WNL.53.5.988, 1:STN:280:DyaK1MvisVGktA%3D%3DCrossRefPubMed
38.
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215, 3344216, 10.1093/nar/16.3.1215, 1:CAS:528:DyaL1cXhsVKlsrs%3DPubMedCentralCrossRefPubMed
39.
Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A (2004) Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 100(1):120–133, 14695733, 10.1097/00000542-200401000-00021, 1:CAS:528:DC%2BD3sXhtVWhtb%2FICrossRefPubMed
40.
Kara I, Sazci A, Ergul E, Kaya G, Kilic G (2003) Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res 111(1–2):84–90, 1:CAS:528:DC%2BD3sXitlWrtrg%3DCrossRef
41.
Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Komatsu H, Sora I, Fukuda K, Koga H, Hanaoka K, Ikeda K (2008) Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9(11):1605–1616, 19018716, 10.2217/14622416.9.11.1605, 1:CAS:528:DC%2BD1cXhsVWjsLjOCrossRefPubMed
42.
Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F (2004) The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48(10):1232–1239, 15504181, 10.1111/j.1399-6576.2004.00517.x, 1:CAS:528:DC%2BD2cXhtVOqtL%2FNCrossRefPubMed
43.
Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J (2006) The mu-opioid receptor gene polymorphism 118A > G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 16(9):625–636, 16906017, 10.1097/01.fpc.0000220566.90466.a2, 1:CAS:528:DC%2BD28XotVWks7s%3DCrossRefPubMed
Metadata
Title
The human μ-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients
Authors
S. Menon
R. A. Lea
B. Roy
M. Hanna
S. Wee
L. M. Haupt
L. R. Griffiths
Publication date
01-10-2012
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 7/2012
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1007/s10194-012-0468-z

Other articles of this Issue 7/2012

The Journal of Headache and Pain 7/2012 Go to the issue

Original

Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study

Original

Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples

Review Article

Future possibilities in migraine genetics

Letter to the Editor

Reply to letter to editor

Original

Body mass index and migraine: a survey of the Chinese adult population

Brief Report

Trigeminal postherpetic neuralgia responsive to treatment with capsaicin 8 % topical patch: a case report